bradykinin B2 receptor — Drug Target

All drugs that target bradykinin B2 receptor — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bradykinin B2 receptor antagonist

Marketed (1)

• ICATIBANT ACETATE
  Icatibant blocks bradykinin from binding to the B2 receptor, reducing HAE symptoms.

Phase 2 pipeline (1)

• HOE140 Icatibant · Sanofi · Bradykinin B2 receptor antagonist · Immunology / Rare Disease
  Icatibant is a selective bradykinin B2 receptor antagonist that blocks the inflammatory effects of bradykinin, a key mediator of angioedema.